An anti-inflammatory drug did not reduce the risk of cardiovascular events. The Phase 3 ZEUS trial showed that Ziltivekimab failed to reduce MACE. An important result for cardiovascular immunology that will trigger plenty of discussion. www.novonordisk.com/news-and-med...
News Details
novonordisk.com